IPO$382.5M IPOBraveheart Bio Prices Upsized $382.5M IPO on NasdaqBraveheart Bio priced its IPO at $18 a share, above range, raising $382.5M for a cardiovascular drug licensed from China's Hengrui Pharmaceuticals -- a sign the biotech IPO window is reopening after two rough years.Aug 6, 2026BRIEF